Superficial Thrombophlebitis of Great Saphenous Vein Following Vaccine

CASE REPORT
Jose Maria Pereira de Godoy, Ana Carolina Pereira de Godoy, Livia Maria Pereira de Godoy, Maria de Fatima Guerreiro Godoy

 
For citation: Pereira de Godoy JM, Pereira de Godoy AC, Pereira de Godoy LM, Guerreiro Godoy MF. Superficial Thrombophlebitis of Great Saphenous Vein Following Vaccine. International Journal of Biomedicine. 2024;14(2):357-358. doi:10.21103/Article14(2)_CR6
 
Originally published June 5, 2024
 

Abstract: 

This paper reports on the occurrence of thrombose of the left great saphenous vein (GSV) soon after being given the AstraZeneca vaccine and two recurrent events within three days after the suspension of the anticoagulant. A 53-year-old patient had superficial thrombophlebitis of the GSV in the left leg three days after taking the second dose of the AstraZeneca vaccine for COVID-19 and initiated treatment with rivaroxaban (XareltoTM) 15 mg twice a day, subsequently increasing to 20 mg. After 45 days, the patient contracted dengue and stopped taking the anticoagulant. Two days later, the patient had another thrombosis in the left GSV. The patient is currently in outpatient care with a prophylactic dose of 10mg/day of anticoagulant and undergoes evaluations at three-month intervals. The result of our study is a rare event.

Keywords: 
superficial thrombophlebitis • great saphenous vein • vaccine
References: 
  1. Bangolo A, Cherian J, Ahmed M, Atoot A, Gupta B, Atoot A. A Case Report of DVT following the Johnson and Johnson Vaccine against the Novel SARS-CoV-2. Case Rep Infect Dis. 2022 May 17;2022:1292754. doi: 10.1155/2022/1292754. PMID: 35620132; PMCID: PMC9130020.
  2. Mani A, Ojha V. Thromboembolism after COVID-19 Vaccination: A Systematic Review of Such Events in 286 Patients. Ann Vasc Surg. 2022 Aug;84:12-20.e1. doi: 10.1016/j.avsg.2022.05.001. Epub 2022 May 11. PMID: 35568325; PMCID: PMC9093198.
  3. Sah MK, Singh BM, Sinha P, Devkota P, Yadav SK, Shrestha J, Shrestha A. Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports. J Med Case Rep. 2022 May 7;16(1):182. doi: 10.1186/s13256-022-03407-6. Erratum in: J Med Case Rep. 2022 Jun 27;16(1):266. PMID: 35524323; PMCID: PMC9076162.
  4. Abbasi S, Alsermani A, Alsegayyir A, Altahan T, Alsermani M, Almustanyir S. Vaccine-Induced Thrombotic Thrombocytopenia: A Case of Splanchnic Veins Thrombosis. Cureus. 2022 Mar 26;14(3):e23507. doi: 10.7759/cureus.23507. PMID: 35494984; PMCID: PMC9038581.5.
  5. Vallone MG, Falcón AL, Castro HM, Ferraris A, Cantarella RF, Staneloni MI, Aliperti VI, Ferloni A, Mezzarobba D, Vázquez FJ, Ratti MFG. Thrombotic events following Covid-19 vaccines compared to Influenza vaccines. Eur J Intern Med. 2022 May;99:82-88. doi: 10.1016/j.ejim.2022.03.002. Epub 2022 Mar 9. PMID: 35288031; PMCID: PMC8904150.
  6. Hungaro Cunha C, Yuri Sato D, Pereira de Godoy JM, da Silva Russeff GJ, Franccini Del Frari Silva D, Pereira de Godoy HJ, Menezes da Silva MO, Amorim Santos H, Guerreiro Godoy MF. Mortality and Deep Vein Thrombosis in the Gamma Variant of Covid 19 and Lung Injury. Vasc Health Risk Manag. 2022 Nov 3;18:833-838. doi: 10.2147/VHRM.S367930. PMID: 36353368; PMCID: PMC9639391.
  7. Pereira de Godoy JM, Russeff GJDS, Cunha CH, Sato DY, Silva DFDF, Godoy HJP, Silva MOMD, Amorim H, Soares MML, Godoy MFG. Increased prevalence of deep vein thrombosis and mortality in patients with Covid-19 at a referral center in Brazil. Phlebology. 2022 Feb;37(1):21-25. doi: 10.1177/02683555211041931. Epub 2021 Sep 8. PMID: 34494482; PMCID: PMC8829736.
  8. Pereira de Godoy JM, Da Silva Russeff GJ, Hungaro Cunha C, Yuri Sato D, Franccini Del Frari Silva D, Guerreiro Godoy MF. Mortality and Change in the Prevalence of Deep Vein Thrombosis Associated With SARS-CoV-2 P.1 Variant. Cureus. 2022 Jul 8;14(7):e26668. doi: 10.7759/cureus.26668. PMID: 35949793; PMCID: PMC9357448.

Download Article
Received April 10, 2024.
Accepted May 18, 2024.
©2024 International Medical Research and Development Corporation.